

## REMARKS

### Status

Claims 1-22 are pending in this application, with Claims 11-14 being withdrawn from consideration.

Support for the amendment to claim 1 can be found in original Claim 7.

Support for the amendment to Claim 9 can be found in Table 1. The compounds amended in Claim 9 correspond to Examples 19-255, 262-307, 311-316, 329-335, 347, 350-390, 396-429, and 433-454 of original Table 1. The examples removed from original table one correspond to compounds that do not fall within the scope of amended Claim 1.<sup>1</sup>

Support for new Claims 15-22 can be found in the original claims and throughout the specification. No new matter will be added upon entry of the above amendments.

### Discussion

Applicants thank the USPTO for indicating that the species of Claim 8 are free of the art. Claim 8 has been amended to be an independent claim. Applicants submit that it should be in allowable condition.

Applicants' representative, David H. Vance, Ph.D., J.D., thanks Examiners Chang and Balls for the helpful and courteous discussion of February 22, 2006. During the discussion it was noted that while proviso (a) of Claim 1, as filed, excluded the Dorsch et al compounds discussed in the current Office Action, there likely should have been a §103 obviousness rejection over Dorsch et al in addition to the §102 anticipation rejection. It was also noted that the Office Action was a bit confusing regarding what part of Claim 7 was searched and considered free of the prior art. In view of the discussion, Applicants' representative noted that the claims would likely be limited to the central cores of Claim 7, except for the ureido core of Dorsch et al or perhaps just to the core of the elected species. The former approach has been taken in the present amendment.

---

<sup>1</sup> Examples 260-261, 308-309, 317-328, and 336-345 were already excluded from Claim 1 as originally filed via proviso. Examples 310, 346, 348-349 were outside of Claim 1 as originally filed. Examples 256-259, 391-395, and 430-432 are now outside of amended Claim 1.

The rejection of Claims 1-7 and 10 under 35 U.S.C. §102(a) over Dorsch et al (WO 2002/48099) has been obviated by appropriate amendment.

Dorsch et al describe compounds having a central ureido-methylene-carbonyl-amino linker (ureido linker). As noted during the discussion, the species cited against the original claims were all excluded by proviso. However, in order to limit any possibility of a Dorsch et al species that falls outside of the original proviso, the ureido linker of Dorsch et al has been removed from the claims. None of the 5 linkers remaining in Claim 1 contain the required ureido group of Dorsch et al or an obvious variant thereof. Thus, Applicants submit that the presently amended claims are neither anticipated nor obvious over Dorsch et al. Withdrawal of this rejection is respectfully requested.

With respect to Claim 9, Applicants have amended this claim to include the compounds of Table 1 that remain within the scope of amended Claim 1.


With respect to the Election/Restriction requirement, Applicants have limited the claims to 5 of the 6 cores of Claim 7, as appears to be suggested on page 2 of the Office Action. Applicants submit that amended claim 1 should now constitute a proper Markush group. Withdrawal of the Markush objection is respectfully requested.

With respect to withdrawn Claims 11-14, Applicants respectfully request rejoinder of Claims 11-14, if allowable subject matter is found in Claims 1-10.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Date: February 27, 2006

Respectfully submitted,



Jing G. Sun, Ph.D.

Registration No. 45,914

Telephone No. (609) 252-3791

Facsimile No. (609) 252-4526

**Please forward all future written correspondence relating to this application to:**

Louis J. Wille  
Patent Department  
Bristol-Myers Squibb Company  
P.O. Box 4000  
Princeton, NJ 08543-4000